JAGX (Jaguar Health Inc.) stock: $0.40, $5.4M market cap, $3.8M cash, $1.6M EV, $6.1M fully diluted market cap. Data from Fully Diluted's biotech stocks database.
What they do
The Company was a majority-owned subsidiary of Napo until the close of the Company's initial public offering on May 18, 2015. The Company was formed to develop and commercialize first-in-class prescription and non-prescription products for companion animals. On July 31, 2017, Jaguar completed a merger with Napo pursuant to the Agreement and Plan of Merger dated March 31, 2017, by and among Jaguar, Napo, Napo Acquisition Corporation (“Merger Sub”), and Napo's representative (the “Merger Agreement”).
Partnerships Future Pak (exclusive US license and supply for Mytesi and Canalevia CA-1, Jan 2026); Knight Therapeutics (exclusive commercialization in Canada and Israel, 15-year term); GEN (license for Eastern Europe territories); Napo Therapeutics (Europe; core mission: access to crofelemer for SBS-IF and MVID orphan indications)
Indications
HIV-associated diarrhea(Approved)
cancer therapy-related diarrhea (prophylaxis)(Phase 3)
microvillus inclusion disease (MVID)(Phase 3)
short bowel syndrome with intestinal failure (SBS-IF)(Phase 3)
Catalysts
— H2 2026
Status note FDA-approved (Mytesi) for symptomatic relief of noninfectious diarrhea in adult HIV/AIDS patients on ART; US commercialization licensed to Future Pak (Jan 2026). Pivotal OnTarget Phase 3 for CTD prophylaxis did not meet its primary endpoint in the prespecified all-tumor analysis; company plans H2 2026 FDA submission of final CSR with breast cancer cohort responder analysis. Two pivotal trials of crofelemer powder for oral solution in MVID (pediatric, ongoing) and SBS-IF; Napo conducting Phase 2 in adult SBS-IF (Italy/Germany).
NP-300
Stage not disclosed · Active
Indications
symptomatic relief of diarrhea from cholera(Stage not disclosed)
Status note Drug product candidate for symptomatic relief of diarrhea from cholera; company using financing proceeds to fund its development. Stage not stated in filing excerpts.
Per-asset detail extracted from the 10-Q filed 2026-08-19. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Specialist fund holders
Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
None of the tracked specialist funds reported a position in the latest 13F snapshot.
Latest news
Loading headlines…
Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 721 stocks.